A detailed history of Geode Capital Management, LLC transactions in Immuneering Corp stock. As of the latest transaction made, Geode Capital Management, LLC holds 209,641 shares of IMRX stock, worth $419,282. This represents 0.0% of its overall portfolio holdings.

Number of Shares
209,641
Previous 221,801 5.48%
Holding current value
$419,282
Previous $283,000 84.45%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$1.03 - $3.21 $12,524 - $39,033
-12,160 Reduced 5.48%
209,641 $522,000
Q2 2024

Aug 09, 2024

SELL
$1.28 - $2.75 $308,120 - $661,977
-240,719 Reduced 52.05%
221,801 $283,000
Q1 2024

May 13, 2024

BUY
$1.91 - $7.32 $34,928 - $133,860
18,287 Added 4.12%
462,520 $1.34 Million
Q4 2023

Feb 13, 2024

BUY
$4.84 - $8.44 $55,800 - $97,304
11,529 Added 2.66%
444,233 $3.27 Million
Q3 2023

Nov 13, 2023

BUY
$7.21 - $10.68 $319,965 - $473,957
44,378 Added 11.43%
432,704 $3.32 Million
Q2 2023

Aug 11, 2023

BUY
$6.49 - $13.36 $1.42 Million - $2.93 Million
219,107 Added 129.48%
388,326 $3.94 Million
Q4 2022

Feb 13, 2023

SELL
$4.09 - $15.0 $1,521 - $5,580
-372 Reduced 0.22%
169,219 $820,000
Q3 2022

Nov 14, 2022

BUY
$5.0 - $14.32 $474,955 - $1.36 Million
94,991 Added 127.33%
169,591 $2.43 Million
Q2 2022

Aug 12, 2022

SELL
$3.89 - $7.81 $637,244 - $1.28 Million
-163,816 Reduced 68.71%
74,600 $403,000
Q1 2022

May 13, 2022

BUY
$6.47 - $16.99 $676,768 - $1.78 Million
104,601 Added 78.17%
238,416 $1.54 Million
Q4 2021

Feb 11, 2022

BUY
$16.12 - $31.02 $185,315 - $356,605
11,496 Added 9.4%
133,815 $2.16 Million
Q3 2021

Nov 12, 2021

BUY
$17.0 - $32.84 $2.08 Million - $4.02 Million
122,319 New
122,319 $3.25 Million

Others Institutions Holding IMRX

About Immuneering Corp


  • Ticker IMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,392,300
  • Market Cap $52.8M
  • Description
  • Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...
More about IMRX
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.